Latest Research And Development News

Austco Healthcare Limited reported a record $81.4 million in revenue for FY25, driven by organic growth and acquisitions including G&S Technologies. EBITDA jumped 62% to $13 million, reflecting strong operational leverage.

Nanosonics delivered a robust FY25 with 17% revenue growth and a 72% jump in profit before tax, propelled by next-gen trophon devices and advancing CORIS commercialisation.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Asset Vision reported robust FY25 results with significant revenue and cash flow growth, achieving a debt-free status while advancing its AI-powered asset management platform.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

Nuix Limited reported an 8% rise in Annualised Contract Value for FY25, driven by a remarkable 132% growth in its Nuix Neo platform. Despite flat revenue, the company achieved a 24.5% increase in Cash EBITDA and outlined a confident outlook for FY26.

Nuix Limited reported a slight revenue increase to $221.5 million for FY25 but swung to a net loss of $9.2 million, weighed down by rising legal fees and restructuring costs. The company’s AI-driven Nuix Neo platform showed strong contract growth, while cash EBITDA improved significantly.

IMDEX Limited posted a modest 3% revenue decline in FY25 but delivered a robust 15% rise in EBITDA and a striking 70% jump in net profit, driven by strong growth in digital and SaaS platforms. The company’s strategic acquisitions and sustained R&D investment position it well for future expansion.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

BrainChip Holdings reports a significant revenue surge and reduced losses in H1 2025, underpinned by new contracts, strategic collaborations, and an expanded funding agreement.